(Q36406543)

14 August 2017

1 reference

title

Antiviral therapy for chronic hepatitis C: past, present, and future (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

Tetsuo Takehara

1 reference

14 August 2017

Norio Hayashi

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

Journal of Gastroenterology

14 August 2017

published in

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

17-27

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-005-1740-7

Is the FXR the fix for cholesterol gallstone disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-005-1740-7

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-005-1740-7

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-005-1740-7

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death

1 reference

12 December 2020

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

12 December 2020

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

12 December 2020

Diagnosis, management, and treatment of hepatitis C

1 reference

12 December 2020

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

12 December 2020

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial

1 reference

12 December 2020

Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study

1 reference

12 December 2020

Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling

1 reference

12 December 2020

Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha

1 reference

12 December 2020

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 December 2020

Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group

1 reference

12 December 2020

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Therapy of hepatitis C: patients with normal aminotransferase levels

1 reference

12 December 2020

Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis

1 reference

12 December 2020

Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group

1 reference

12 December 2020

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

1 reference

12 December 2020

Optimal therapy of hepatitis C.

1 reference

12 December 2020

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

1 reference

12 December 2020

Outcomes of interferon and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

1 reference

12 December 2020

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

12 December 2020

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

12 December 2020

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

12 December 2020

Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France

1 reference

12 December 2020

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

12 December 2020

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

12 December 2020

Natural killer cells in hepatitis C virus infection: from innate immunity to adaptive immunity

1 reference

12 December 2020

Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo

1 reference

12 December 2020

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

1 reference

12 December 2020

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

12 December 2020

Side effects of alpha interferon in chronic hepatitis C.

1 reference

12 December 2020

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

12 December 2020

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C.

1 reference

12 December 2020

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

12 December 2020

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial.

1 reference

12 December 2020

Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon

1 reference

12 December 2020

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

12 December 2020

Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer

1 reference

12 December 2020

Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy

1 reference

12 December 2020

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

12 December 2020

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

12 December 2020

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

12 December 2020

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

1 reference

12 December 2020

Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine Protease

1 reference

12 December 2020

The significance of interferon and ribavirin combination therapy followed by interferon monotherapy for patients with chronic hepatitis C in Japan

1 reference

12 December 2020

Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial

1 reference

12 December 2020

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver

1 reference

12 December 2020

Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects

1 reference

12 December 2020

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

12 December 2020

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

12 December 2020

10.1007/S00535-005-1740-7

Identifiers

DOI

1 reference

14 August 2017

1 reference